Loading this company
AbbVie Inc.
ABBVPrices in USD
TickerWorth ScoreC50/100
What we think
Priced above our range of $149.59 to $208.96.
Price
$285.42USD up +$2.02 (+0.71%)
Quoted · Prices are delayed.
Why did it move today?
Nothing we can cite explains today’s move for this company.
Is it cheap?
Our range from 3 models, on today’s numbers
$149.59–$208.96
What the price needs: revenue growth of 19.7%/yr for 5 years (our model assumes 6.9%).
Led by discounted cash flow (DCF) · Steady cash-flow business
Price $285.42Priced · Prices are delayed.
Is it a good business?
- Valuation0 out of 100
- Growth100 out of 100
- Financial health0 out of 100
- Dividend50 out of 100
- Past performance100 out of 100
Bull, base, bear
Our forward range over 12 months is part of Pro. See plans
The street
Analysts’ mean target
$282.61 across 28 analysts
The high and low of the analyst range is part of Pro. See plans
What does it do?
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It operates in the Drug Manufacturers - General industry (Healthcare sector), headquartered in United States. The company employs roughly 57,000 people.
Key stats
52-week range$190.75–$291.40
- Open
- $283.61
- Day high
- $286.64
- Day low
- $283.00
- Previous close
- $283.40
- Volume
- 5,638,833 · 1.16× avg
- Average volume
- 4,843,490
- Market cap
- $504,370,659,328.00
- P/E (TTM)
- 80.63
- Earnings per share
- $3.54
- Beta
- 0.23
Prices are delayed. The feed does not say when these figures were taken.
What’s the latest?
- Changed leadership or its board
- Reported quarterly or annual results
- Issued a public disclosure (Reg FD)
- Disclosed another material event
- Disclosed another material event
- Reported quarterly or annual results
- Reported quarterly or annual results
Top news
No recent headlines we can cite for this company.
Insider trades
The 90-day buying-and-selling read is part of Pro. See plans
- Donoghoe NicholasOption exercise · $2,584,744.20
- Donoghoe NicholasOpen-market sale ·
Not investment advice. TickerWorth Score is a model output.